Chronic myeloid leukaemia (CML) incidence statistics

Cases

New cases of chronic myeloid leukaemia, 2014, UK

 

Proportion of all cases

Percentage chronic myeloid leukaemia is of total cancer cases, 2014, UK

 

Age

Peak rate of chronic myeloid leukaemia cases, 2012-2014, UK

 

 

Trend over time

Change in chronic myeloid leukaemia cancer incidence rates since the early 1990s, UK

Chronic myeloid leukaemia (CML) accounts for less than 1% of all new cancer cases in the UK, and 8% of all leukaemia types combined (2014).[1-4]

In 2013, there were 748 new cases of CML in the UK: 438 (59%) in males and 310 (41%) in females, giving a male:female ratio of around 12:10.[1-4] The crude incidence rate Open a glossary item shows that there is around 1 new CML case for every 100,000 males in the UK, and less than 1 for every 100,000 females.

For males European age-standardised incidence rates Open a glossary item (AS rates) are significantly higher in Wales compared with other UK countries. Rates do not differ significantly between the other constituent countries of the UK for either sex.[1-4]

Chronic Myeloid Leukaemia (C92.1), Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK, 2014

England Wales Scotland Northern Ireland UK
Male Cases 365 35 30 8 438
Crude Rate 1.4 2.3 1.2 0.9 1.4
AS Rate 1.5 2.6 1.2 1.0 1.5
AS Rate - 95% LCL 1.4 1.7 0.8 0.3 1.4
AS Rate - 95% UCL 1.7 3.4 1.7 1.6 1.7
Female Cases 266 13 26 5 310
Crude Rate 1.0 0.8 0.9 0.5 0.9
AS Rate 1.0 0.8 0.9 0.6 1.0
AS Rate - 95% LCL 0.9 0.4 0.6 0.1 0.9
AS Rate - 95% UCL 1.1 1.2 1.3 1.1 1.1
Persons Cases 631 48 56 13 748
Crude Rate 1.2 1.6 1.0 0.7 1.2
AS Rate 1.2 1.6 1.1 0.7 1.2
AS Rate - 95% LCL 1.1 1.1 0.8 0.3 1.1
AS Rate - 95% UCL 1.3 2.1 1.4 1.2 1.3

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item

For chronic myeloid leukaemia, there are few established risk factors therefore differences between countries largely reflect differences in diagnosis and data recording.

References

  1. Data were provided by the Office for National Statistics on request, June 2016. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases.
  2. Data were provided by ISD Scotland on request, May 2016. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, June 2016. Similar data can be found here: http://www.wcisu.wales.nhs.uk
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2016. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/

About this data

Data is for: UK, 2014, ICD-10 C92.1

Last reviewed:

Chronic myeloid leukaemia (CML) incidence is strongly related to age, with the highest incidence rates being in older males and females. Almost half (48%) of chronic myeloid leukaemia cases in the UK each year are diagnosed in people aged 65 and over (2012-2014).[1-4]

Age-specific incidence rates rise gradually from birth and more steeply from around age 55-59, with the highest rates in the 85-89 age group for males and 90+ age group for females. Incidence rates are higher for males than for females at age 25-29, 70-74 and 80+, with few significant differences in younger age groups. The gap is widest at age 25-29, when the male: female ratio of age-specific incidence rates (to account for the different proportions of males to females in each age group) is around 24:10.[1-4]

Chronic Myeloid Leukaemia (C92.1), Average Number of New Cases per Year and Age-Specific Incidence Rates, UK, 2012-2014

For CML, like most cancer types, incidence increases with age. This largely reflects cell DNA damage accumulating over time. Damage can result from biological processes or from exposure to risk factors. A drop or plateau in incidence in the oldest age groups often indicates reduced diagnostic activity perhaps due to general ill health.

References

  1. Data were provided by the Office for National Statistics on request, June 2016. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases.
  2. Data were provided by ISD Scotland on request, May 2016. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, June 2016. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2016. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2012-2014, ICD-10 C92.1

Last reviewed:

Chronic myeloid leukaemia (CML) incidence rates have decreased by 33% in the UK since the early 1990s.[1-3] This includes a larger overall increase for males than for females. Chronic myeloid leukaemia incidence rates increased by 36% (persons) in Great Britain between 1979-1981 and 1991-1993.[1-3]

For males, European age-standardised Open a glossary item (AS) incidence rates decreased by 38% between 1993-1995 and 2003-2005 and have since remained stable – leaving rates in 2012-2014 39% lower compared with 1993-1995. For females, the pattern is similar with rates decreasing by 31% between 1993-19895 and 2003-2005, and since remaining stable– leaving rates in 2012-2014 30% lower compared with 1993-1995.

Over the last decade in the UK (between 2003-2005 and 2012-2014), CML AS incidence rates have remained stable for males and females combined and separately.[1-3,6]

Chronic Myeloid Leukaemia (C92.1), European Age-Standardised Incidence Rates, UK, 1993-2014

CML incidence rates have remained stable overall for people aged 50-59 and under in the UK since the early 1990s, and decreased overall for older age groups.[1-3] The largest decreases have been in people aged 80+ with European AS incidence rates falling by 58% between 1993-1995 and 2012-2014.

Chronic Myeloid Leukaemia (C92.1), European Age-Standardised Incidence Rates, by Age, UK, 1993-2014

For chronic myeloid leukaemia there are few established risk factors, therefore increasing incidence in the 1980s and 1990s may largely reflect improvements in diagnosis and data recording, plus changes in the definition of CML.

References

  1. Data were provided by the Office for National Statistics on request, June 2016. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, May 2016. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/ 
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, June 2016. Similar data can be found here: http://www.wcisu.wales.nhs.uk
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2016. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/

About this data

Data is for UK, 1993-2014, ICD-10 C92.1

Last reviewed:

The lifetime risk of developing chronic myeloid leukaemia (CML) is around 1 in 840 for men and around 1 in 1,180 for women, in 2012 in the UK.[1]

The lifetime risk for CML has been calculated on the assumption that the possibility of having more than one diagnosis of CML over the course of a lifetime is very low (‘Current Probability’ method).[2]

References

  1. Lifetime risk estimates calculated by the Statistical Information Team at Cancer Research UK. Based on data provided by the Office of National Statistics, ISD Scotland, the Welsh Cancer Intelligence and Surveillance Unit and the Northern Ireland Cancer Registry, on request, December 2013 to July 2014.
  2. Esteve J, Benhamou E and Raymond L. Descriptive epidemiology. IARC Scientific Publications No.128, Lyon, International Agency for Research on Cancer, pp 67-68 1994.
Last reviewed:

There is no evidence for an association between chronic myeloid leukaemia (CML) incidence and deprivation for either males or females in England.[1] England-wide data for 2006-2010 show European age-standardised Open a glossary item  incidence rates are similar for both males and females living in the most deprived areas compared with the least deprived.[1]

Chronic Myeloid Leukaemia (C92.1), European Age-Standardised Incidence Rates by Deprivation Quintile, England, 2006-2010

The estimated deprivation gradient in CML incidence between people living in the most and least deprived areas in England has not changed in the period 1996-2010.[1]

Reference

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for: England, 2006-2010, ICD-10 C92.1

Deprivation gradient statistics were calculated using incidence data for 2006-2010. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

An estimated 6,000 people who had been diagnosed with chronic myeloid leukaemia (CML) between 1991 and 2010 were alive in the UK at the end of 2010.[1]

References

  1. Macmillan Cancer Support and National Cancer Registration and Analysis Service. Cancer Prevalence UK Data Tables. London: NCRAS; 2015.

About this data

Data is for: Great Britain (1991-2010) and Northern Ireland (1993-2010), ICD-10 C92.1

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 2.2 out of 5 based on 10 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page